2013 DEC 2 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- New research on Immune System Diseases and Conditions is the subject of a report. According to news reporting originating in Bethesda, Maryland, by NewsRx editors, the research stated, "This article discusses HIV vaccine discovery and candidate vaccine testing in the context of current realities of funding and clinical trial practice. Lacking perfect animal models for testing candidate HIV vaccines, clinical investigators have proposed a strategy of iterative exploratory clinical trials in the model of cancer chemotherapy development."
The news reporters obtained a quote from the research from the National Institute of Allergy and Infectious Diseases (NIAID), "Problems with the appropriateness of this model to HIV vaccine development are discussed. Also, the future feasibility of this strategy in the context of increasing clinical trial costs and emerging new, efficacious prevention modalities is questioned. Strategies for making better use of animal models are presented as an alternative to iterative exploratory clinical efficacy testing. Some ways in which better data from preclinical studies can refine clinical product development are described. Finally, development of an HIV vaccine under the FDA's 'Animal Rule' pathway to licensure when human efficacy studies are not feasible is discussed as a fall-back approach."
According to the news reporters, the research concluded: "Not making a preventive vaccine against HIV infection is simply not an option because eradication of AIDS will require a preventive vaccine."
For more information on this research see: HIV Vaccine Development: Strategies for Preclinical and Clinical Investigation. Aids Research and Human Retroviruses, 2013;29(11):1401-1406. Aids Research and Human Retroviruses can be contacted at: Mary Ann Liebert, Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA. (Mary Ann Liebert, Inc. - www.liebertpub.com; Aids Research and Human Retroviruses - www.liebertpub.com/overview/aids-research-and-human-retroviruses/2/)
Our news correspondents report that additional information may be obtained by contacting S.Z. Shapiro, NIAID, Vaccine Res Program, Div Aids, Bethesda, MD 20892, United States (see also Immune System Diseases and Conditions).
Keywords for this news article include: Drugs, Bethesda, Maryland, HIV/AIDS, Vaccines, Virology, RNA Viruses, Chemotherapy, Retroviridae, United States, HIV Infections, Pre-Trial Research, Vertebrate Viruses, Biological Products, Primate Lentiviruses, North and Central America, Clinical Trials and Studies, Acquired Immunodeficiency Syndrome
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC